Skip to main content

Table 1 Characterization of patients with Alzheimer’s disease and healthy normal control subjects

From: Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42

 

AD

Healthy normal control subjects

Total sample number

24

29

Sex

 Female

13 (54.2%)

16 (55.2%)

 Male

11 (45.8%)

13 (44.8%)

Age, years (SD)

67.6 (±7.4)

62.4 (±5.7)

Education, years (SD)

13.1 (±3.9)

13.2 (±3.5)

CDR-SOB, mean

6.35

0.03

MMSE score, mean

17.7

29.03

ApoE ε4, %

47.8

21.7

 Note test

1

0

Number of plasma samples

24

29

CSF markers

23

28

 Aβ42, pg/ml, mean (SD)

258.6 (±70.8)

464.8 (±114.4)

 p-Tau, pg/ml, mean (SD)

58.6 (±18.6)

28.0 (±14.3)

 t-Tau, pg/ml, mean (SD)

132.1 (±61.8)

62.1 (±20.3)

PiB-PET number

23

28

 Mean SUVR

1.57

1.14

FDG-PET number

18

28

 Mean SUVR

0.9

1.06

  1. Abbreviations: Aβ 42 Amyloid-β 1–42 peptide, AD Alzheimer’s disease, ApoE Apolipoprotein E, CDR-SOB Clinical Dementia Rating Sum of Boxes, CSF Cerebrospinal fluid, FDG 18F-fluorodeoxyglucose, MMSE Mini Mental State Examination, PET Positron emission tomography, PiB 11C-Pittsburgh compound B, p-Tau Phosphorylated tau protein, SUVR Standardized uptake value ratio, t-Tau Total tau protein